Viking Therapeutics up 58% after Madrigal announces NASH trial data

Shares of Viking Therapeutics (VKTX) are up $2.34, or 58%, to $6.36 after competitor Madrigal Pharmaceuticals (MDGL) announced topline results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. MAESTRO-NASH, a registrational Phase 3 trial, achieved both liver histological improvement endpoints that FDA proposed as reasonably likely to predict clinical benefit to support accelerated approval for the treatment NASH with liver fibrosis, Madrigal reported earlier this morning. In morning trading, shares of Madrigal Pharmaceuticals are up $168.03, or 263%, to $231.83.